AbbVie Inc. (ABBV) is currently trading at $253.30. Based on 28 Wall Street analysts, the average target price is $266.89, implying a 5.4% upside. The consensus recommendation is BUY.

ABBV

AbbVie Inc.

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$253.30

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$235.00$300.00
Current $253.30
Median: $273.00Mean: $270.05Current: $253.30

Recent price target updates (latest 80)

  • Canaccord GenuityJul 22, 2026

    PT action: Raises

    $273.00 → $282.00

  • CitigroupJul 15, 2026

    PT action: Raises

    $230.00 → $260.00

  • UBSJul 13, 2026

    PT action: Raises

    $230.00 → $260.00

  • BMO CapitalJul 13, 2026

    PT action: Raises

    $258.00 → $300.00

  • B of A SecuritiesJul 10, 2026

    PT action: Raises

    $234.00 → $276.00

  • RBC CapitalJul 10, 2026

    PT action: Raises

    $260.00 → $280.00

  • Wells FargoJul 10, 2026

    PT action: Raises

    $260.00 → $295.00

  • GuggenheimJul 9, 2026

    PT action: Raises

    $249.00 → $261.00

  • JP MorganJul 9, 2026

    PT action: Raises

    $260.00 → $280.00

  • Cantor FitzgeraldJul 6, 2026

    PT action: Raises

    $240.00 → $265.00

  • Piper SandlerJun 23, 2026

    PT action: Maintains

    $298.00 → $298.00

  • Canaccord GenuityJun 23, 2026

    PT action: Raises

    $265.00 → $273.00

  • Evercore ISI GroupMay 15, 2026

    PT action: Lowers

    $236.00 → $235.00

  • Piper SandlerMay 14, 2026

    PT action: Raises

    $294.00 → $298.00

  • Evercore ISI GroupMay 4, 2026

    PT action: Raises

    $232.00 → $236.00

  • GuggenheimMay 1, 2026

    PT action: Maintains

    $249.00 → $249.00

  • Canaccord GenuityApr 30, 2026

    PT action: Raises

    $262.00 → $265.00

  • Morgan StanleyApr 30, 2026

    PT action: Raises

    $270.00 → $278.00

  • Cantor FitzgeraldApr 30, 2026

    PT action: Maintains

    $240.00 → $240.00

  • Piper SandlerApr 23, 2026

    PT action: Lowers

    $299.00 → $294.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$266.89

Based on 28 analysts

Analyst Recommendations

Buy (24)Hold (6)Sell (1)

Upside

+5.37%

Market Cap

$447.53B

Financial & Investment Metrics

Next Earnings Date
Jul 31, 2026D-9
P/E Ratio (TTM)123.56
Forward P/E15.56
P/B RatioN/A
Dividend Yield2.70%
Return on Equity (ROE)N/A
Operating Margin32.16%
Debt to EquityN/A
Beta (Volatility)0.28
52 Week Range$186.77 - $261.64
LowCurrent: $253.30High

Latest News

Daily editorial mentioning ABBV

Price target moves

Healthcare and Tech Dominate as 24 Target Revisions Hit the Wire

The latest sentiment shift across the S&P 500 has been active, with 24 distinct ticker price targets adjusted over the last 14 days, according to data as of July 13, 2026. The activity is concentrated in the Healthcare and IT sectors, where institutional analysts are re-evaluating long-term valuation models despite recent price volatility.

Target changes

The moves reflect a mix of cautious recalibration and optimistic outlooks. UBS was particularly busy, issuing a series of upward revisions for healthcare heavyweights. Notably, the firm boosted LLY from 1250 to 1425 and VRTX from 545 to 585. Meanwhile, TD Cowen took a more selective approach, raising ADI to 460 from 450 while simultaneously lowering its outlook on ISRG twice in the same window—first to 600 and then to 520, signaling significant disagreement within the firm's own modeling trajectory.

Ticker Firm Dir Prior → Current
TSLA Jefferies Up 375 → 400
ISRG TD Cowen Down 585 → 520
FTNT TD Cowen Up 160 → 215
NFLX Oppenheimer Down 120 → 100

Industrial names also saw downward pressure, as TD Cowen trimmed its targets for both LMT and NOC, moving them to 560 and 580, respectively. In the communication services space, the outlook remains fragmented; while UBS lowered GOOGL to 400, the broader market volatility has left some price action feeling disconnected from recent fundamental adjustments.

How this differs from consensus

When we look at the spread between these new targets and the current consensus mean, it is clear that some analysts are leaning into extreme outcomes. For instance, the recent downgrade of NFLX to 100 by Oppenheimer sits at a striking variance compared to the broader market's expectations. This move suggests a fundamental questioning of subscriber growth narratives that the consensus has yet to fully internalize. Conversely, the aggressive upward revision for FTNT to 215 by TD Cowen highlights a divergence in how analysts account for cyber-security demand, placing the firm far ahead of the average valuation model. These target adjustments serve as a reminder that institutional consensus is often a lagging indicator, prone to rapid shifts when firm-level analysts pivot their core growth assumptions.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
3/4/2026PURDUE DAVID RYANOfficerSale at price 233.56 per share.5,230
3/2/2026SIATIS PERRY C.General CounselSale at price 233.51 - 235.26 per share.18,668
2/25/2026SIATIS PERRY C.General CounselSale at price 230.00 per share.22,381
8/12/2025SALEKI-GERHARDT AZITAChief Operating OfficerSale at price 198.42 per share.42,370
8/5/2025DONOGHOE NICHOLASOfficerSale at price 198.27 - 198.59 per share.13,295
3/31/2025STEWART JEFFREY RYANOfficerSale at price 209.49 - 210.54 per share.58,832
3/14/2025REENTS SCOTT T.Chief Financial OfficerSale at price 212.34 per share.17,644
3/3/2025SIATIS PERRY C.General CounselSale at price 205.38 - 210.00 per share.27,900
3/3/2025GONZALEZ RICHARD ADirectorSale at price 205.11 - 210.53 per share.98,628
3/3/2025RICHMOND TIMOTHY JOfficerSale at price 209.80 - 211.32 per share.21,250

Frequently Asked Questions

Q. What is the current target price and upside for ABBV?

A. The current target price for AbbVie Inc. is $266.89, which implies a 5.4% upside from the current price of $253.30. This is based on the consensus of 28 Wall Street analysts.

Q. What is the current analyst recommendation for ABBV?

A. Currently, there are 8 Strong Buy, 16 Buy, 6 Hold, 0 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying ABBV stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer